Valid as of today A00-250 Cheatsheet that never go wrong.

Killexams.com gives you the legitimate, Latest, and 2022 refreshed SAS Platform Administration for SAS9 free pdf download and gave a 100 percent Guarantee. Anyway, 24 hours practice with VCE test system is required. Simply download A00-250 Exam Questions and Latest Topics from your download segment and begin rehearsing. It will simply require 24 hours to prepare you for a genuine A00-250 test.

Exam Code: A00-250 Practice test 2022 by Killexams.com team
A00-250 SAS Platform Administration for SAS9

Exam Name SAS Certified Platform Administrator for SAS 9
Exam Code A00-250
Exam Duration 110 minutes
Exam Questions 70 multiple-choice and short-answer questions
Passing Score 70%

Successful candidates should be able to:
Secure the SAS configuration on each server machine.
Check status and operate servers.
Monitor server activity and administer logging.
Establish formal, regularly scheduled backup processes.
Add users and manage their access.
Establish connectivity to data sources.
Set up and secure metadata folder structures.
Administer repositories and move metadata.

Exam Contents
Securing the SAS configuration
Secure a SAS platform configuration.
Update SAS Software
Monitoring the Status and Operation of SAS Metadata Servers
Manage metadata repositories.
Identify the properties and functionality of SAS servers.
Configure a SAS Metadata server cluster.
Monitoring, Logging, and Troubleshooting SAS Servers
Monitor SAS servers.
Administer SAS server logging and modify logging configurations.
Troubleshoot basic SAS server issues such as server availability.
Backing Up the SAS Environment
Backup and restore the SAS environment.
Administering Users
Manage connection profiles.
Manage roles.
Register users and groups in the metadata.
Give users access to processing servers and data servers.
Determine when to store passwords in the metadata.
Manage internal SAS accounts.
Identify SAS server authentication mechanisms.
Administering Data Access
Register libraries and tables in the metadata.
Update table metadata.
Pre-assign a library.
Troubleshoot data access problems.
Use the metadata LIBNAME engine.
Managing Metadata
Identify how the metadata authorization layer interacts with other security layers.
Identify where, how, and to whom metadata permissions are assigned.
Determine the outcome of metadata authorization decisions.
Use metadata permissions to secure metadata.
Create and use Access Control Templates.
Promote metadata and associated content.

SAS Platform Administration for SAS9
SASInstitute Administration test Questions
Killexams : SASInstitute Administration test Questions - BingNews https://killexams.com/pass4sure/exam-detail/A00-250 Search results Killexams : SASInstitute Administration test Questions - BingNews https://killexams.com/pass4sure/exam-detail/A00-250 https://killexams.com/exam_list/SASInstitute Killexams : Use of the Postpartum Depression Screening Scale in a Collaborative Obstetric Practice

Methods

The study setting was a high-volume collaborative obstetrics and midwifery practice in Albuquerque, New Mexico, with 11 obstetricians and nine nurse-midwives. This group attends about 2000 deliveries per year, and approximately 40% of all clients were enrolled in the Medicaid program. The race/ethnicity profile of the clinical population ( Table 3 ) reflects the diversity of the greater Albuquerque area.[17]

The PPD screening tool was the PDSS developed by Beck and Gable.[16,18] This tool was chosen for ease of use and because phrases in the questions were taken from women's own words. Beck and Gable determined that PDSS cutoffs should be set so as to minimize false negative screens. The authors believed the potential risks of failing to detect a depressed mother far outweigh the risks involved in labeling a normal mother as depressed.[18] This tool is a 35-item Likert-type instrument created for new mothers. It takes 5 to 10 minutes for women to answer, and it is written at a third grade studying level. The PDSS contains short, easy to understand items so that mothers may respond by using a 5-point scale ranging from "strongly disagree" to "strongly agree." The tool yields scores that fall into one of three ranges: normal adjustment (≤ 59), potential symptoms of PPD (60 - 79) and a positive screen for major PPD (≥ 80). A score of ≥ 80 on the PDSS does not diagnose PPD or depression equivalent to a DSM-IV-TR diagnosis of Major Depressive Disorder with Postpartum Onset. However, it does indicate that the woman has a high probability of depression and should be referred to a mental health clinician for assessment and treatment. Beck and Gable tested the validity of the PDSS by having a nurse psychotherapist interview women using the Structural Clinical Interview for DSM-IV Axis 1 Disorders. They found that a PDSS cut-off score of ≥ 80 has a sensitivity of 94% and specificity of 98%. In other words, 94% of women who scored ≥ 80 on the PDSS were diagnosed with major PPD based on the interviews with the nurse psychotherapist, and 98% who scored < 80 on the PDSS did not meet the criteria for major PPD. A PDSS score between 60 and 79 yielded a sensitivity of 91% and specificity of 72% for a diagnosis of minor PPD.[19] The PDSS also provides scores in seven symptom areas: sleeping/eating disturbances, anxiety/insecurity, emotional lability, mental confusion, loss of self, guilt/shame, and suicidal thoughts.[16]

This study was approved by the institutional review board at Presbyterian Healthcare Services, Albuquerque, New Mexico. The PDSS tool was purchased by a grant from the Presbyterian Foundation. A training session that included an overview of PPD, the purpose of a screening tool, an overview of the research protocol, and how to administer and score the PDSS tool was held for all obstetricians, certified nurse-midwives, and medical assistants. We developed a PDSS process flow sheet (Figure 1) to facilitate the administration and scoring of the PDSS, as well as a plan to refer patients with a positive screen for PPD for definitive diagnosis and treatment by mental health professionals. Essential to our study was the creation of a list of available mental health clinicians who had expertise in the treatment of depression, particularly PPD. The project directors were a clinical nurse specialist in psychiatry and a certified nurse-midwife from the collaborative practice, and this combination provided a bridge across the disciplines.

Postpartum Depression Screening Scale. MHP = Mental health provider. (Figure by C. Byrne.)

The medical assistants introduced the research study and PDSS tool to women at the 6-week postpartum office visit. A signed consent form, which included informed consent and the authorization for the disclosure of personal health information, was obtained from each participant. Medical assistants asked the woman to complete the first seven questions (short form) of the PDSS and scored the results. If a woman scored ≤ 13, the clinician discussed these normal results with the patient, and no referral or follow-up was deemed necessary. If a woman scored ≥ 14, she was asked to complete the remaining 28 questions, and the tool was scored by either the medical assistant or the clinician. If women scored ≤ 59 on the full questionnaire, the clinician discussed these normal results and no referral or follow-up was necessary. Women who scored in the "potential symptoms of PPD" category on the full screening tool (a score of 60 - 79) were informed about PPD and encouraged to increase their support, sleep, and nutrition. They were asked to notify their clinician if symptoms worsened. The score was then documented in the chart along with the plan of care. In the case of a positive screen (≥ 80 or more, indicating a risk for major PPD), PPD was discussed with women, available treatment options were reviewed, and a referral was made to a mental health professional for further evaluation and treatment. The questionnaires and consent forms were placed in the PDSS study folder and collected by the researchers for data entry.

Once the study was underway the researchers conducted a series of semi-structured interviews with clinicians and medical assistants in order to understand their experience using the screening tool and their perceptions of the benefits and difficulties of using the tool in a busy clinical practice. These interviews were then transcribed and themes were developed and a simple summation of the most frequently mentioned items were categorized.

The researchers collected the completed PDSS forms, which had the women's names on them. Each form was assigned an identification number, and the data were entered into an Excel spreadsheet (Microsoft, Redmond, WA), using the identification number only, that included the PDSS score and specific demographic and clinical items. These included age, parity, race/ethnicity, education, marital status, infant feeding, type of delivery, and history of depression. After data entry, all records were kept in a locked file.

The analysis was performed by experienced personnel at University of New Mexico using SAS software version 9 (SAS Institute, Inc., Cary, NC) on a mainframe computer. Analysis included descriptive statistics, the χ2 test to assess differences in proportions for category of maternal characteristics by PDSS score (negative, symptoms present, or positive screen for PPD), and logistic regression using a backward elimination strategy. This latter method included significant study variables in a regression model, and systematically eliminated one at a time based on lack of statistical significance in the presence of the other variables. The final result indicated significant predictors for a positive screen for PPD using the PDSS in our clinical setting.

Sat, 21 May 2022 08:03:00 -0500 en text/html https://www.medscape.com/viewarticle/563220_2
Killexams : Why Do Women Miss Oral Contraceptive Pills? An Analysis of Women's Self-Described Reasons for Missed Pills

Methods

Data for this secondary analysis were drawn from an earlier study by Potter et al.[11] That study was approved by the University of Michigan Human Subjects Institutional Review Board, and all subjects gave informed consent at that time.

At the beginning of the original study, participants completed a baseline questionnaire and received a free cycle of pills in a dispenser with an electronic monitoring device that recorded the time and date of pill taking. They also received a monthly diary card on which to record how many pills were taken each day, days when menstrual bleeding occurred, reasons for missed pills, side effects, days when sexual intercourse occurred, and any backup method of contraception used. Details on the electronic monitoring device can be found in the earlier report.[11] At the end of each of the next two pill cycles, participants completed another questionnaire and received another free cycle of pills and monthly diary card. A final questionnaire was completed at the end of the third cycle. The questionnaires recorded demographic, reproductive, and psychosocial information.

Sample

Women initiating pill use either for the first time or after a 6-month hiatus from the method were recruited from a university health service and a publicly-funded clinic in Michigan and North Carolina during 1993 to 1994.[11] All participants were aged 18 or older and voluntarily chose OCs as their method of birth control. After giving informed consent, 168 women enrolled in the original study. Of the 103 women included for analysis in the original study, women were, on average, 20.9 years of age and had 13.7 years of education. They were most likely to be white and not married. However, distribution of these characteristics differed significantly among women from the student health and public health centers.

Monthly diary cards for 147 participants were retrieved for the current analysis. We excluded 6 participants because their diary cards indicated fewer than 17 days of continuous pill taking. Questionnaires completed by participants and the data files from the original study were no longer available at the time of this analysis. Therefore, we could not determine further demographic details about individual subjects, including race, marital status, and education.

Measures

Information collected from individual diary cards included the number and days of missed active pills, total number of days enrolled in the study, self-reported reasons for missing pills, whether placebo pills were taken, and whether two pills were taken the day following a missed pill. Weekend misses were defined as those misses occurring on a Friday, Saturday, or Sunday. If the previous pill miss was 1 day earlier than the current miss, then that miss was counted as a consecutive miss. For instance, if 3 days of pills were missed in a row, 2 consecutive misses were recorded. Consecutive misses were defined as occurring on the weekend only if the first day missed occurred on a Friday through Sunday. Although some participants recorded reasons for missing placebo pills, such reasons were excluded from analysis in this study.

We sorted reasons for missed pills into 15 notional categories using criteria of independent and nonoverlapping abstraction, as agreed upon by both authors ( Table 1 ). The reason "unknown blank" included instances in which participants left blank the number of pills taken on a specific day and provided no reason for the missing data. "No reason" included those instances in which participants indicated a pill was missed on a specific day but provided no reason for the missed pill. The 15 categories were further grouped into 3 primary categories for more statistically valid analysis: physiological, unavailable, and other ( Table 1 ).

To investigate the reasons women provide for missing OC pills, we considered all instances of missed pills, thus including multiple observations for participants who reported missing pills on more than one occasion. The instance was further classified according to whether it significantly increased the user's risk for pregnancy. Following the Food and Drug Administration's (FDA) directions for pill taking, we assumed that those women who took pills late and those who missed an occasional single pill were not necessarily at an increased risk for pregnancy. The instance was classified as increasing risk of pregnancy if the respondent had missed 2 or more consecutive pills, had not taken two pills the day after a pill was missed, and had not given "late" as the reason for a missed pill.

Data Analysis

Data were analyzed by using software from the SAS Institute (Statistical Analysis System, Cary, NC). Frequency distributions of responses for different subgroups and cross-tabulations of responses for different questions (e.g., differences in reasons for missing one active pill versus reasons for missing consecutive pills) were tested for statistical significance by the χ2 procedure. Analyses of variance (ANOVA) were conducted to test the relationship between the percentage of missed pills, the percentage of consecutive misses, the percentage of women taking two pills the day after a missed pill, and whether women took placebo pills consistently.

Tue, 14 Jun 2022 12:00:00 -0500 en text/html https://www.medscape.com/viewarticle/513205_2
Killexams : Autologous Transplantation and Maintenance Therapy in Multiple Myeloma

Patients

Figure 1. Figure 1. Randomization, Treatment, and Follow-up of the Enrolled Patients.

MPR denotes melphalan–prednisone–lenalidomide.

A total of 402 patients were enrolled; 399 entered the common induction and mobilization phase, and 273 remained eligible for random assignment to consolidation therapy with high-dose melphalan or MPR. At the end of consolidation therapy, 251 patients were also eligible for the randomized comparison between maintenance therapy and no maintenance therapy (Figure 1). Baseline demographic and disease characteristics were well balanced among the treatment groups (Table S2 in the Supplementary Appendix). At the data cutoff point, 237 patients had disease progression or had died, 45 patients (23%) were still receiving lenalidomide maintenance therapy, and 24 patients (11%) were not receiving maintenance therapy. The median duration of follow-up from the time of enrollment was 51.2 months (range, 1 to 66).

Efficacy

Figure 2. Figure 2. Kaplan–Meier Estimates of Progression-free Survival and Overall Survival.

Panel A shows progression-free survival and 5-year overall survival from the time of diagnosis among patients who received high-dose melphalan followed by lenalidomide maintenance therapy, those who received high-dose melphalan with no subsequent maintenance therapy, those who received MPR followed by lenalidomide maintenance therapy, and those who received MPR with no subsequent maintenance therapy. Panel B shows progression-free survival and 4-year overall survival from the start of consolidation therapy. Panel C shows progression-free survival and 3-year overall survival from the start of maintenance or no maintenance. The median progression-free survival is shown within the graph in the left side of each panel. CI denotes confidence interval.

In the total enrolled population (402 patients), the median progression-free survival from the time of diagnosis was 54.7 months among patients who received high-dose melphalan plus lenalidomide maintenance therapy, 37.4 months among patients who received high-dose melphalan without maintenance therapy, 34.2 months among patients who received MPR plus lenalidomide maintenance therapy, and 21.8 months among patients who received MPR without maintenance therapy (Fig. 2A). The 5-year overall survival rate was 78.4% among patients who received high-dose melphalan plus lenalidomide maintenance therapy, 66.6% among patients who received high-dose melphalan without maintenance therapy, 70.2% among patients who received MPR plus lenalidomide maintenance therapy, and 58.7% among patients who received MPR without maintenance therapy (Fig. 2A).

At the end of the induction and mobilization phase, the random assignment to high-dose melphalan or MPR was disclosed for the 273 patients who were eligible for consolidation therapy. The median progression-free survival was significantly longer among patients who received high-dose melphalan (43.0 months) than among patients who received MPR (22.4 months; hazard ratio for progression or death, 0.44; 95% confidence interval [CI], 0.32 to 0.61; P<0.001) (Figure 2B). High-dose melphalan, as compared with MPR, was also associated with improvement in the 4-year overall survival rate (81.6% vs. 65.3%; hazard ratio for death, 0.55; 95% CI, 0.32 to 0.93; P=0.02) (Fig. 2B). The progression-free survival benefit associated with high-dose melphalan was consistent across all patient subgroups (Fig. S2 in the Supplementary Appendix).

Among the 251 patients who were eligible to be included in the second randomized comparison (between lenalidomide maintenance therapy and no maintenance therapy), median progression-free survival was significantly longer with lenalidomide maintenance therapy than with no maintenance therapy (41.9 months vs. 21.6 months; hazard ratio for progression or death, 0.47; 95% CI, 0.33 to 0.65; P<0.001) (Figure 2C). Lenalidomide maintenance therapy, as compared with no maintenance therapy, had no significant effect on the 3-year overall survival rate (88.0% vs. 79.2%; hazard ratio for death, 0.64; 95% CI, 0.36 to 1.15; P=0.14) (Figure 2C). The beneficial effect of lenalidomide maintenance on progression-free survival was homogeneous in all subgroups except patients with stage III disease at the time of diagnosis (P=0.04 for the interaction between stage and treatment) (Fig. S2 in the Supplementary Appendix). Results of the subgroup analysis of overall survival are shown in Figure S3 in the Supplementary Appendix.

No significant differences in progression-free survival were detected between the maintenance and no-maintenance populations in the comparison of high-dose melphalan with MPR (P=0.99 for interaction) (Fig. S2 in the Supplementary Appendix), or between the high-dose melphalan and MPR subgroups in the comparison of lenalidomide maintenance therapy with no maintenance therapy (P=0.93 for interaction) (Fig. S2 in the Supplementary Appendix). Among patients with relapsed multiple myeloma, the 3-year overall survival rates from the time of relapse were similar across the four treatment groups (Fig. S4 in the Supplementary Appendix). In the MPR group, 98 of 156 patients (62.8%) received high-dose melphalan at relapse, as prespecified in the treatment protocol. Details of salvage treatment administered at the time of relapse are provided in Table S3 in the Supplementary Appendix.

The complete response rate improved from 15.7% after consolidation therapy to 35.7% after maintenance therapy in the high-dose melphalan group and from 20.0% after consolidation therapy to 33.8% after maintenance therapy in the MPR group (data not shown). Prognostic factors such as staging and cytogenetic features did not affect the quality of the response.

Safety

Table 1. Table 1. Grade 3 and 4 Adverse Events Occurring in at Least 2% of the Safety Population.

During the induction phase, the most frequent grade 3 or 4 adverse events were neutropenia (in 8.5% of the patients), anemia (in 6.3%), infection (in 6.0%), and dermatologic events (in 4.8%); one death occurred as a result of arrhythmia. In total, 27 of 399 patients (6.8%) discontinued treatment because of adverse events, and 56 (14.0%) discontinued treatment for other reasons (withdrawal of consent or the investigator’s decision) (Table 1).

During consolidation therapy, hematologic adverse events occurred more frequently in patients who received high-dose melphalan than in those who received MPR. These events were mainly grade 3 or 4 neutropenia (94.3% vs. 51.5%, P<0.001) and thrombocytopenia (93.6% vs. 8.3%, P<0.001) (Table 1). Other grade 3 or 4 adverse events that were more common in patients who received high-dose melphalan were gastrointestinal events (18.4% vs. 0%, P<0.001), infections (16.3% vs. 0.8%, P<0.001), and systemic events (12.8% vs. 1.5%, P<0.001).

During the maintenance phase, the most frequent grade 3 or 4 adverse events were neutropenia (in 23.3% of patients who received lenalidomide maintenance therapy vs. 0% of patients who received no maintenance therapy, P<0.001), infections (in 6.0% vs. 1.7%, P=0.09), and dermatologic events (in 4.3% vs. 0%, P=0.03) (Table 1). Reduced doses of lenalidomide were required in 14.7% of patients (Table S5 in the Supplementary Appendix); 5.2% of patients discontinued lenalidomide because of toxicity (Table S6 in the Supplementary Appendix).

Eleven patients (2.8%) had a second primary cancer: lung cancer in one patient during induction; prostate cancer in two patients and breast cancer in three patients during lenalidomide maintenance therapy; and one case each of myelodysplasia, lung cancer, bladder cancer, colon cancer, and biliary tract cancer after consolidation therapy in patients who were randomly assigned to no maintenance therapy.

Wed, 13 Jul 2022 12:00:00 -0500 en text/html https://www.nejm.org/doi/full/10.1056/NEJMoa1402888
Killexams : Want to Accelerate Students’ Learning? Don’t Forget About Wraparound Services

School and district leaders pushing for accelerated learning may not be thinking about the role that wraparound services for kids and their families—mental health counseling, food banks, transportation, and small group instruction—play in making sure their efforts are successful.

But they should be, concludes a report presented at the International Society for Technology in Education’s annual conference here.

Those wraparound services were pivotal to the success of Lindsay Unified, a high-poverty school district in California’s central valley, where students generally made progress during virtual instruction, even as kids in other districts with similar demographics lost academic ground, said Beth Holland, one of the study’s authors and a partner at the nonprofit Learning Accelerator in an interview.

The strategies can be applied to the kind of accelerated learning many districts are focusing on now.

If “we aren’t addressing the real needs of the whole child, how are we going to expect them to be able to engage in [the] kind of deep learning” needed for acceleration, she said. She and her co-author, Caitlin McLemore, an education technology consultant, analyzed historical data from iReady, an instructional platform which offers online assessments, to determine how Lindsay students fared during the pandemic.

Particularly eye-catching: While in many places, students classified as English language learners, migrants, or homeless, struggled during the 2020-21 school year, in Lindsay Unified those students generally advanced academically.

“These differences in progress are striking and certainly a testament to the efforts of the district to ensure that learners continued to grow during distance learning,” said the report.

When the pandemic hit in March of 2020, the district made sure every child had a working Chromebook and access to the internet, and provided paper, pencils, books, crayons, and more to students at home.

What’s more, even when schools remained largely virtual, the district allowed small cohorts of students to return to the building where they could participate in online learning in a classroom along with a handful of their peers and a paraprofessional or other staff member who could help ensure that the virtual instruction went smoothly.

Parent communication was also a cornerstone of the district’s strategy. School counselors and staff told the researchers there was “regular, constant” communication with families and care-givers through text messaging, phone, evening Zoom meetings, and even home visits.

Lindsay Unified does not have particularly high student achievement compared with more advantaged districts. And elementary school students generally advanced further than older kids.

Still, Lindsay’s emphasis on wraparound supports—and the study’s focus on student progress rather than overall achievement—could provide a model for other districts looking to strengthen and evaluate their acceleration efforts, Holland said.

“I think the big piece is that it’s replicable, this idea that we are focusing on growth rather than a single test score,” Holland said. “And how do we really celebrate that progress? Because when we think about acceleration, we want to accelerate growth. We’re not necessarily trying to accelerate a number.”

Mon, 27 Jun 2022 08:22:00 -0500 en text/html https://www.edweek.org/leadership/want-to-accelerate-students-learning-dont-forget-about-wraparound-services/2022/06
Killexams : Litigation: Editor's Picks Killexams : Special Report | Law.com
Special Reports ›

Our global newsroom covers litigation at every level, from bet-the-company cases involving multinational litigants to local personal injury lawsuits with statewide implications. Here you'll find the best of our litigation trend analysis and in-depth commentary from practitioners and judges, along with our coverage of key players, breaking news, game-changing rulings, major recoveries and international cases.

Share This Page

  • Analysis

    Did the Supreme Court's 'Arthrex' Decision Open Pandora's Box?

    Robert E. Browne, Jr. and Ryan C. Deck | July 11, 2022

    The Patent and Trademark Office has indicated that guidance on discretionary denials at the PTAB will be released soon, clarifying how different factors are applied when patent judges use their discretion to turn away cases.

  • News

    With Guns, Abortion and Religion, Judges Become the New Historians

    Marcia Coyle | June 27, 2022

    "The run-of-the-mill judge anywhere in the United States is not going to have the knowledge to say this [restriction or regulation] is wrong or right unless there's the odd judge who has read a lot of history," one scholar of American history said. "Their political views will undoubtedly tell them how to evaluate this, what to use. It's very cynical, but true."

  • News

    New Lawsuits Latch Onto Infant Formula Recall

    Amanda Bronstad | March 03, 2022

    At least four class actions and one pre-suit petition have been filed over a Feb. 17 recall that Abbott announced after three babies were hospitalized and one died after ingesting its Similac, Alimentum and EleCare brands of infant formula.

  • News

    Drug Companies Move Forward on $26B Opioid Deal

    Amanda Bronstad | February 25, 2022

    Johnson & Johnson and three drug distributors—AmerisourceBergen, Cardinal Health and McKesson—agreed on Friday to move forward with the second largest multistate settlement in U.S. history after 90% of cities and counties signed up to obtain funds to combat the opioid crisis.

  • News

    10th Cir. Reinstates Robocall Class Action Following SCOTUS 'Ford' Ruling

    Allison Dunn | January 05, 2022

    "We understand 'Ford' to adopt the proposition that the forum State can exercise personal jurisdiction over an out-of-state defendant that has injured a resident plaintiff in the forum State if (1) the defendant has purposefully directed activity to market a product or service at residents of the forum State and (2) the plaintiff's claim arises from essentially the same type of activity, even if the activity that gave rise to the claim was not directed at forum residents," the appeals court said.

  • In Mass Torts, All Eyes Are on Talc Bankruptcy in 2022

    Amanda Bronstad | December 21, 2021

    Lawyers for talc claimants have moved to dismiss the Chapter 11 case, filed by LTL Management, a newly created subsidiary of Johnson & Johnson, to resolve more than 38,000 lawsuits alleging that its talcum powder products cause ovarian cancer or mesothelioma.

  • News

    Winning Lawyer Says Victim Blaming Fueled $44M Houston Verdict

    Katheryn Hayes Tucker | November 24, 2021

    “On balance, we think Hilton has a responsibility here,” plaintiffs attorney Ed Blizzard recounted telling the jury. “What kind of hotel makes an error like this, and puts a woman in the wrong room, and then she is sexually assaulted, blames her? They didn't really treat her as a human being, much less as a guest in the hotel.”

  • How COVID-19 Court Protocols Are Catching Up With Litigators

    Alaina Lancaster | March 10, 2022

    Attorneys are facing fresh judicial ire for failing to comply with protocols earlier in the pandemic. Meanwhile, some top trial lawyers are warning that court backlogs could create an existential crisis for the profession.

  • News

    Lawsuits Over Premature Infant Formula Deaths Are Growing

    Amanda Bronstad | January 14, 2022

    Nearly 50 lawsuits allege Abbott Laboratories and Mead Johnson made false statements about the safety of their cow’s milk-based infant formula, which studies have found caused a gastrointestinal inflammation called necrotizing enterocolitis, or NEC, in premature babies.

  • In Mass Torts, All Eyes Are on Talc Bankruptcy in 2022

    Amanda Bronstad | December 21, 2021

    Lawyers for talc claimants have moved to dismiss the Chapter 11 case, filed by LTL Management, a newly created subsidiary of Johnson & Johnson, to resolve more than 38,000 lawsuits alleging that its talcum powder products cause ovarian cancer or mesothelioma.

  • How Law Schools Are Preparing Students for the 'New Status Quo' of Virtual Litigation

    Christine Charnosky | December 16, 2021

    “We have hosted eight large-scale trial competition tournaments since the pandemic began which translates to literally hundreds of trials over Zoom,” a Fordham Law spokesperson said. “Add to that the countless practice trials, and our students have gained more online litigation skills than 99% of the lawyers practicing today.”

  • News

    With Guns, Abortion and Religion, Judges Become the New Historians

    Marcia Coyle | June 27, 2022

    "The run-of-the-mill judge anywhere in the United States is not going to have the knowledge to say this [restriction or regulation] is wrong or right unless there's the odd judge who has read a lot of history," one scholar of American history said. "Their political views will undoubtedly tell them how to evaluate this, what to use. It's very cynical, but true."

  • Opioid Judge 'Clearly Abused His Discretion,' Appeals Court Says

    Amanda Bronstad | March 11, 2022

    The U.S. Court of Appeals for the Sixth Circuit on Friday issued a mandate against U.S. District Judge Dan Polster, who is overseeing 3,000 opioid lawsuits in multidistrict litigation, for failing to address hundreds of remand motions pending before him for more than three years.

  • News

    New Lawsuits Latch Onto Infant Formula Recall

    Amanda Bronstad | March 03, 2022

    At least four class actions and one pre-suit petition have been filed over a Feb. 17 recall that Abbott announced after three babies were hospitalized and one died after ingesting its Similac, Alimentum and EleCare brands of infant formula.

  • News

    What Do Judges Think About Jury Trials Right Now?

    Amanda Bronstad | January 24, 2022

    As the COVID-19 omicron variant has swept through the country in January, judges have had to grapple with whether to move forward with jury trials right now. Their reasons are as varied as the public's views about the pandemic.

  • News

    Senate Confirms Gabriel Sanchez to 9th Circuit

    Avalon Zoppo | January 12, 2022

    During his nomination hearing, Republicans repeatedly pressed Sanchez on his work in Gov. Jerry Brown's office, overseeing the adoption of regulations implementing California's Proposition 57.

  • News

    Profile

    Who Is Judge James Selna and Why Is His Trial Record Under Review?

    Meghann M. Cuniff | January 10, 2022

    A rule change in the Central District of California ended an unusual practice of other judges deciding recusal motions targeting their colleagues. Now an unusual request in Michael Avenatti's cross-country criminal cases is putting a California trial record before a judge in the Southern District of New York.

  • News

    House Judiciary Leaders Urge SCOTUS to Investigate 11th Circuit's Hiring of Clerk With History of Racist Remarks

    Katheryn Hayes Tucker | November 10, 2021

    “While the above actions are worrying in the extreme, we want to make clear that the focus of this letter is not the individual who was hired but, rather, the members of the federal judiciary who chose to hire her,” Nadler and Johnson said. “This past conduct was clearly publicly available by the time of these judges’ hiring decisions. If the judges were not aware of their law clerk’s widely reported record, their negligent hiring practices present their own set of problems with the judiciary.”

  • News

    West Virginia Judge Rules for Drug Distributors in Opioid Case

    Amanda Bronstad | July 05, 2022

    U.S. District Judge David Faber, in a bench trial that concluded last year in the Southern District of West Virginia, sided with distributors McKesson, Cardinal Health and AmerisourceBergen in a 184-page decision about the opioid crisis.

  • This Big Law Settlement Ends 'A Cautionary Tale'

    Dan Packel | May 19, 2022

    Even without a revealing trial, the contours of the dispute between UnitedLex and a bankruptcy trustee for LeClairRyan supply law firms and new law providers guideposts for do's and don'ts when collaborating.

  • Federal Judge Asks State Court to Weigh in on COVID-19 Business Interruption Case

    Mason Lawlor | May 02, 2022

    A large majority of courts nationwide have sided with insurers in the latest string of pandemic-driven business interruption cases. Nevertheless, a federal judge has asked the Maryland Court of Appeals to weigh in on whether the COVID-19 virus causes "physical loss or damage" to a property such that it triggers coverage.

  • News

    Could Boeing Be Sued Over China Eastern Crash?

    Amanda Bronstad | March 29, 2022

    Although the cause of this month’s crash of a China Eastern Airlines plane remains unknown, lawyers who previously sued over the 737 Max 8 said there are early signs of a possibly defective Boeing aircraft.

  • News

    10th Circ. Upholds Dismissal of Consumer Class Action Against Champion Petfoods

    Allison Dunn | February 18, 2022

    The trial judge had acknowledged that a jury is usually the one to determine whether a statement is false or misleading, but said the plaintiffs' statements were "'so general or devoid of specific factual content,' they are incapable of empirical verification and cannot, 'as a matter of law, supply rise to liability.'"

  • News

    10th Cir. Reinstates Robocall Class Action Following SCOTUS 'Ford' Ruling

    Allison Dunn | January 05, 2022

    "We understand 'Ford' to adopt the proposition that the forum State can exercise personal jurisdiction over an out-of-state defendant that has injured a resident plaintiff in the forum State if (1) the defendant has purposefully directed activity to market a product or service at residents of the forum State and (2) the plaintiff's claim arises from essentially the same type of activity, even if the activity that gave rise to the claim was not directed at forum residents," the appeals court said.

  • News

    Talc Cases Halted as J&J Bankruptcy Moves to New Jersey

    Amanda Bronstad | November 10, 2021

    A bankruptcy judge on Wednesday ordered that all talcum powder lawsuits be stayed for 60 days, pending transfer of the Chapter 11 filing of Johnson & Johnson subsidiary LTL Management from North Carolina to New Jersey.

  • News

    Washington Settles Opioid Case for $518 Million

    Amanda Bronstad | May 03, 2022

    Tuesday’s announcement, from Attorney General Bob Ferguson, comes after the state wrapped up a bench trial against the distributors last month but before King County Superior Court Judge Michael Scott had ruled on the case.

  • News

    Who Gets the $2.3 Billion in Legal Fees in the Global Opioid Deal?

    Amanda Bronstad | March 11, 2022

    The fees and costs outlined in the $26 billion opioid deal with Johnson & Johnson's Janssen Pharmaceuticals and three distributors are a mix of common benefit fees, contingency fees and payments to the states for outside counsel. One law professor said, "it’s not like the lawyers are going to be impoverished.”

  • News

    Drug Companies Move Forward on $26B Opioid Deal

    Amanda Bronstad | February 25, 2022

    Johnson & Johnson and three drug distributors—AmerisourceBergen, Cardinal Health and McKesson—agreed on Friday to move forward with the second largest multistate settlement in U.S. history after 90% of cities and counties signed up to obtain funds to combat the opioid crisis.

  • News

    Winning Lawyer Says Victim Blaming Fueled $44M Houston Verdict

    Katheryn Hayes Tucker | November 24, 2021

    “On balance, we think Hilton has a responsibility here,” plaintiffs attorney Ed Blizzard recounted telling the jury. “What kind of hotel makes an error like this, and puts a woman in the wrong room, and then she is sexually assaulted, blames her? They didn't really treat her as a human being, much less as a guest in the hotel.”

More from ALM

Legal Speak is a weekly podcast that makes sense of what’s happening in the legal industry.

2 minute read

1 minute read

1 minute read

Wed, 13 Jul 2022 06:02:00 -0500 en text/html https://www.law.com/special-reports/litigation-coverage/?slreturn=20220618151305
Killexams : Insights on the $89 Bn Healthcare Analytics Market is Expected to Grow at a CAGR of over 20.9% During 2022-2028 | Vantage Market Research

WASHINGTON, June 21, 2022 (GLOBE NEWSWIRE) -- Vantage Market Research's latest analysis of the Global Healthcare Analytics Market finds that the increasing technological advancements are expediting the Healthcare Analytics Market growth in coming years.

In addition, growing government initiatives, and increasing pressure to reduce health care costs are also anticipated to augment the growth of the Global Healthcare Analytics Market during the forecast period.

The Global Market revenue stood at a value USD 28.5 Billion in the year 2021.

The Global Healthcare Analytics Market size is forecasted to reach USD 89 Billion by the year 2028 and is expected to grow exhibiting a Compound Annual Growth Rate (CAGR) of 20.9% during the forecast period; states Vantage Market Research, in a report, titled "Healthcare Analytics Market Size, Share & Trends Analysis Report by Type (Descriptive Analytics, Predictive Analytics, Prescriptive Analytics, Cognitive Analytics), by Application (Clinical Analytics, Financial Analytics, Operation and Administrative Analytics, Population Health), by Component (Services, Hardware, Software), by Deployment Model (On-Premise, On-Demand), by End User (Payers, Providers, ACOs, HIEs, Mcos and TPAs), by Region (North America, Europe, Asia Pacific, Latin America) - Global Industry Assessment (2016 - 2021) & Forecast (2022 - 2028)".

Please Check Out Our Free demo Reports and Make a More Informed Decision:

Get Access to a Free Copy of Our Latest demo Report @ https://www.vantagemarketresearch.com/healthcare-analytics-market-1664/request-sample

(Sample reports are a great way to test our in-depth reports or study before you make a purchase)

  • The newly updated, 145+ page reports provide an in-depth analysis of the COVID-19 virus and pandemic.
  • Using industry data and interview with experts, you can learn about Topics such as regional impact analysis, global forecast, competitive landscape analysis, size & share of regional markets.
  • We offer these reports in PDF format so you can read them on your computer and print them out.
  • Free demo includes, Industry Operating Conditions, Industry Market Size, Profitability Analysis, SWOT Analysis, Industry Major Players, Historical and Forecast, Growth Porter's 5 Forces Analysis, Revenue Forecasts, Industry Trends, Industry Financial Ratios.
  • The report also presents the country-wise and region-wise analysis of the Vantage Market Research and includes a detailed analysis of the key factors affecting the growth of the market.
  • Sample Report further sheds light on the Major Market Players with their Sales Volume, Business Strategy and Revenue Analysis, to offer the readers an advantage over others.

Market Dynamics:

Driver:

Rising Technological Advancements to Drive the Market Growth

Over the past few years, the global market has seen a dramatic increase in the demand for a healthcare analytical system. The rapid rate of technological advancement and the massive investment of the healthcare industry in IT development and digitalization are key factors in the rapid growth of the healthcare sector. Analysis platforms are currently distributed by health facilities around the world, assisting in patient management, maintenance, due to the best care that can be provided. The distribution of health care analysis platforms not only increases staff productivity, but overall patient management has improved and the burden on caregivers has been reduced. It can not only Excellerate the quality of patient care but also provide information on the overall management of business facilities, better patient access, disease control etc. Hence, the rise in technology advancements is the crucial driver for the growth of the market.

Increasing Government initiatives to Stimulate Market Growth

Government efforts and major financial fluctuations in the healthcare industry also encourage the renaming and are responsible for the increased acceptance of these analysis platforms by health facilities. Analytical forums are used not only by hospitals but also by other institutions for the management and interpretation of clinical data from the various studies conducted; to study historical data and analyse it to identify trends, to develop methods, tools and technologies for best results.

These areas of analysis are also used by policy makers to learn statistics and models to make better decisions and policies regarding health care facilities and to provide care to patients. The U.S. government has been taking steps to address this case as the HealthData.gov website contains information from a few state-owned databases on Topics such as public health practices, clinical data, medical information, and engineering information that are accessible through application applications. Therefore, the implementation of these programs is considered a good indicator of market growth as a whole.

Key Insights & Findings from the Report:

  • According to our primary respondents' research, the Healthcare Analytics market is predicted to grow at a CAGR of roughly 20.9% during the forecast period.
  • The Healthcare Analytics market was estimated to be worth roughly USD 28.5 Billion in 2021 and is expected to reach USD 89 Billion by 2028; based on primary research.   
  • On the basis of region, North America is projected to dominate the worldwide Healthcare Analytics market.

Purchase This Premium Report (Price 4500 USD for a single-user license) at @ https://www.vantagemarketresearch.com/buy-now/healthcare-analytics-market-1664/0

Benefits of Purchasing Healthcare Analytics Market Reports:       

  • Customer Satisfaction: Our team of experts assists you with all your research needs and optimizes your reports.
  • Analyst Support: Before or after purchasing the report, ask a professional analyst to address your questions.
  • Assured Quality: Focuses on accuracy and quality of reports.
  • Incomparable Skills: Analysts provide in-depth insights into reports.

Segmentation of the Global Healthcare Analytics Market:

  • Type
    • Descriptive Analytics
    • Predictive Analytics
    • Prescriptive Analytics
    • Cognitive Analytics
  • Application
    • Clinical Analytics
    • Financial Analytics
    • Operation and Administrative Analytics
    • Population Health
  • Component
    • Services
    • Hardware
    • Software
  • Deployment Model
  • End User
    • Payers
    • Providers
    • ACOs, HIEs, Mcos and TPAs
  • Region
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East & Africa

Read Full Research Report @ https://www.vantagemarketresearch.com/industry-report/healthcare-analytics-market-1664

COVID-19 Impact Analysis:

The COVID-19 outbreak has affected various industries worldwide. Governments across the world implemented strict lockdown measures and social distancing norms in order to restrict the swift spread of the pandemic. Manufacturing facilities around the world were shut down during the initial stages of the pandemic. Moreover, the economic crisis after the pandemic might lead to a significant delay in the commercial roll-out of the IT healthcare industry. Small and medium-scale companies are the backbone of technology providers and are witnessing a steep drop in revenue since the emergence of the pandemic in 2020. Hence, market players faced numerous challenges as disruptions in the supply chain were observed. However, things will Excellerate in the second half of 2022 as more supplies will come online. The impact of COVID-19 on the market demand is considered while estimating the current and forecast market size and growth trends of the market for all the regions and countries based on the following data points:

  1. Impact Assessment of COVID-19 Pandemic
    1. North America
    2. Europe
    3. Asia Pacific
    4. Latin America
    5. Middle East & Africa
  2. Quarterly Market Revenue Forecast by Asia Pacific 2020 & 2021
  3. Key Strategies Undertaken by Companies to Tackle COVID-19
  4. Long Term Dynamics
  5. Short Term Dynamics

The report on Healthcare Analytics Market highlights:

  • Assessment of the market
  • Premium Insights
  • Competitive Landscape
  • COVID Impact Analysis
  • Historic Data, Estimates and Forecast
  • Company Profiles
  • Global and Regional Dynamics

Regional Analysis:

North America Dominated the Global Healthcare Analytics Market

North America dominated the Global Healthcare Analytics Market in 2021 and is likely to continue the same trend during the forecast period. This is attributable to the increase in implementation of organizational health regulations that promote the adoption of HCIT solutions in the region. Furthermore, the increasing focus on PHM, greater VC investment along with growing pressure to reduce health care costs is also likely to support the regional growth of the market. Additionally, the high availability of products and services and presence of leading players is also expected to fuel the growth of the market in the region.

Browse market data Tables and Figures spread through 150 Pages and in-depth TOC on "Healthcare Analytics Market Size, Share & Trends Analysis Report by Type (Descriptive Analytics, Predictive Analytics, Prescriptive Analytics, Cognitive Analytics), by Application (Clinical Analytics, Financial Analytics, Operation and Administrative Analytics, Population Health), by Component (Services, Hardware, Software), by Deployment Model (On-Premise, On-Demand), by End User (Payers, Providers, ACOs, HIEs, Mcos and TPAs), by Region (North America, Europe, Asia Pacific, Latin America) - Global Industry Assessment (2016 - 2021) & Forecast (2022 - 2028)".

List of Prominent Players in Healthcare Analytics Market:

  • IBM (US)
  • Optum (US)
  • Cerner (US)
  • SAS Institute (US)
  • Allscripts (US)
  • McKesson (US)
  • Mede Analytics (US)
  • Inovalon (US)
  • Oracle (US)
  • Health Catalyst (US)
  • SCIO Health Analytics (US)
  • Cotiviti (formerly Verscend Technologies) (US)
  • CitiusTech (US)
  • Wipro (India)
  • Vitreos Health (US)
  • Linguamatics (US)
  • Flatiron (US)
  • Roam Analytics (US)
  • Komodo Health (US)
  • CVS Health (US)

Recent Developments:

July 2021: Enlitic (US) got in partnership with NMC Healthcare (UAE). This is a multi-faceted partnership with private healthcare companies to implement Enlitic solutions in GCC countries.

June 2021: Flatiron (US) collaborated with Foundation Medicine, Inc. to integrate its solutions with OncoEMR to provide customers with integrated genetic profiles.

April 2020: Cerner announced the acquisition Kantar Health. With this discovery, Cerner plans to compile data to Excellerate the safety and effectiveness of clinical research in health sciences, medicine, and health care. This acquisition is expected to add to your service delivery.

January 2020: Optum and Change Healthcare, a healthcare technology provider, announced their partnership. Under this partnership, Change Healthcare will join Optum Insight in delivering software and data analysis, technology-based services, research, and revenue management cycle offerings to strengthen Optum's healthcare analysis portfolio.

Key questions answered in the report:

  • Which regional market will show the highest and rapid growth?
  • Which are the top five players of the Healthcare Analytics Market?
  • How will the Healthcare Analytics Market change in the upcoming six years?
  • Which application and product will take a lion's share of the Healthcare Analytics Market?   
  • What is the Healthcare Analytics market drivers and restrictions?   
  • What will be the CAGR and size of the Healthcare Analytics Market throughout the forecast period?    

This market titled "Healthcare Analytics Market" will cover exclusive information in terms of Regional Analysis, Forecast, and Quantitative Data – Units, Key Market Trends, and various others as mentioned below:

Parameter Details
Market Size Provided for Years 2016-2028
Base Year 2021
Historic Years 2016-2020
Forecast Years 2022-2028
Segments Covered • Type

   • Descriptive Analytics

   • Predictive Analytics

   • Prescriptive Analytics

   • Cognitive Analytics

• Application

   • Clinical Analytics

   • Financial Analytics

   • Operation and Administrative Analytics

   • Population Health

• Component

   • Services

   • Hardware

   • Software

• Deployment Model

   • On-Premise

   • On-Demand

• End User

   • Payers

   • Providers

   • ACOs, HIEs, Mcos and TPAs

• Region

   • North America

   • Europe

   • Asia Pacific

   • Latin America

   • Middle East & Africa

Region & Counties Covered • North America

    • U.S.

    • Canada

    • Mexico

• Europe

    • U.K

    • France

    • Germany

    • Italy

    • Spain

    • Rest Of Europe

• Asia Pacific

    • China

    • Japan

    • India

    • South Korea

    • South East Asia

    • Rest Of Asia Pacific

• Latin America

    • Brazil

    • Argentina

    • Rest Of Latin America

• Middle East & Africa

    • GCC Countries

    • South Africa

    • Rest Of Middle East & Africa

Companies Covered • IBM (US)

• Optum (US)

• Cerner (US)

• SAS Institute (US)

• Allscripts (US)

• McKesson (US)

• MedeAnalytics (US)

• Inovalon (US)

• Oracle (US)

• Health Catalyst (US)

• SCIO Health Analytics (US)

• Cotiviti (formerly Verscend Technologies) (US)

• CitiusTech (US)

• Wipro (India)

• VitreosHealth (US)

• Linguamatics (US)

• Flatiron (US)

• Roam Analytics (US)

• Komodo Health (US)

• CVS Health (US)

Report Coverage Market growth drivers, restraints, opportunities, Porter's five forces analysis,
PEST analysis, value chain analysis, regulatory landscape, technology landscape,
patent analysis, market attractiveness analysis by segments and North America,
company market share analysis, and COVID-19 impact analysis

Customization of the Report:

The report can be customized as per client needs or requirements. For any queries, you can contact us on sales@vantagemarketresearch.com or +1 (202) 380-9727. Our sales executives will be happy to understand your needs and provide you with the most suitable reports.

Download Free demo Report Now @ https://www.vantagemarketresearch.com/healthcare-analytics-market-1664/request-sample

Browse More Related Report:   

  • Cross-Border B2C E-Commerce Market to Reach Valuation of USD 3,042.2 Million by 2028 - The growth of online stores and e-commerce purchasing is Driving the Market Growth.
  • Cannabis Testing Market to Reach USD 2,669.45 Million by 2028.
  • B2B Payments Market to Reach 1,618.15 USD Billion by 2028.
  • Electric Truck Market to Reach Valuation of USD 1686.6 Million by 2028 - The Government's Focus on Zero-Emission Cars and Rules will Encourage the Use of Electric Trucks in the E-Commerce and Automotive Industries.
  • Ethanol Market to Reach Valuation of USD 117.5 Billion by 2028 – Changing Lifestyle and Disposable Income among the Global Population Drives the Market.
  • Green Hydrogen – The Future Fuel Set to Witness 50 - Fold Growth Increasing Investments & Government Policies to Boost Global Green Hydrogen Market.
  • Green Chemicals Market to Reach Valuation of 16684.27 USD Million by 2028; Increasing Adoption of Packaging Which is Bio-based is Driving the Market.

About Vantage Market Research:

We, at Vantage Market Research, provide quantified B2B high quality research on more than 20,000 emerging markets, in turn, helping our clients map out constellation of opportunities for their businesses. We, as a competitive intelligence market research and consulting firm provide end to end solutions to our client enterprises to meet their crucial business objectives. Our clientele base spans across 70% of Global Fortune 500 companies. The company provides high quality data and market research services. The company serves various enterprises and clients in a wide variety of industries. The company offers detailed reports on multiple industries including Chemical Materials and Energy, Food and Beverages, Healthcare Technology, etc. The company's experienced team of Analysts, Researchers, and Consultants use proprietary data sources and numerous statistical tools and techniques to gather and analyse information.

Follow Us on LinkedIn: https://www.linkedin.com/company/vantage-market-research/

Follow Us on Twitter: https://twitter.com/vantagemarketr

Contact us

Eric Kunz

6218 Georgia Avenue NW Ste 1 - 564

Washington DC 20011-5125

United States Tel: +1 202 380 9727

Email: sales@vantagemarketresearch.com

Website: https://www.vantagemarketresearch.com/

Latest Vantage Market Research Press Releases @https://www.vantagemarketresearch.com/insight/press-releases

Latest Vantage Market Research Blog @ https://www.vantagemarketresearch.com/insight/blogs

Blog:


© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Mon, 20 Jun 2022 23:16:00 -0500 text/html https://www.benzinga.com/pressreleases/22/06/g27791107/insights-on-the-89-bn-healthcare-analytics-market-is-expected-to-grow-at-a-cagr-of-over-20-9-durin
Killexams : Insights on the $89 Bn Healthcare Analytics Market is Expected to Grow at a CAGR of over 20.9% During 2022-2028 | Vantage Market Research

Vantage Market Research, The North Star for the Working World

WASHINGTON, June 21, 2022 (GLOBE NEWSWIRE) -- Vantage Market Research’s latest analysis of the Global Healthcare Analytics Market finds that the increasing technological advancements are expediting the Healthcare Analytics Market growth in coming years.

In addition, growing government initiatives, and increasing pressure to reduce health care costs are also anticipated to augment the growth of the Global Healthcare Analytics Market during the forecast period.

The Global Market revenue stood at a value USD 28.5 Billion in the year 2021.

The Global Healthcare Analytics Market size is forecasted to reach USD 89 Billion by the year 2028 and is expected to grow exhibiting a Compound Annual Growth Rate (CAGR) of 20.9% during the forecast period; states Vantage Market Research, in a report, titled “Healthcare Analytics Market Size, Share & Trends Analysis Report by Type (Descriptive Analytics, Predictive Analytics, Prescriptive Analytics, Cognitive Analytics), by Application (Clinical Analytics, Financial Analytics, Operation and Administrative Analytics, Population Health), by Component (Services, Hardware, Software), by Deployment Model (On-Premise, On-Demand), by End User (Payers, Providers, ACOs, HIEs, Mcos and TPAs), by Region (North America, Europe, Asia Pacific, Latin America) - Global Industry Assessment (2016 - 2021) & Forecast (2022 - 2028).

Please Check Out Our Free demo Reports and Make a More Informed Decision:

Get Access to a Free Copy of Our Latest demo Report @ https://www.vantagemarketresearch.com/healthcare-analytics-market-1664/request-sample

(Sample reports are a great way to test our in-depth reports or study before you make a purchase)

  • The newly updated, 145+ page reports provide an in-depth analysis of the COVID-19 virus and pandemic.

  • Using industry data and interview with experts, you can learn about Topics such as regional impact analysis, global forecast, competitive landscape analysis, size & share of regional markets.

  • We offer these reports in PDF format so you can read them on your computer and print them out.

  • Free demo includes, Industry Operating Conditions, Industry Market Size, Profitability Analysis, SWOT Analysis, Industry Major Players, Historical and Forecast, Growth Porter's 5 Forces Analysis, Revenue Forecasts, Industry Trends, Industry Financial Ratios.

  • The report also presents the country-wise and region-wise analysis of the Vantage Market Research and includes a detailed analysis of the key factors affecting the growth of the market.

  • Sample Report further sheds light on the Major Market Players with their Sales Volume, Business Strategy and Revenue Analysis, to offer the readers an advantage over others.

Market Dynamics:

Driver:

Rising Technological Advancements to Drive the Market Growth

Over the past few years, the global market has seen a dramatic increase in the demand for a healthcare analytical system. The rapid rate of technological advancement and the massive investment of the healthcare industry in IT development and digitalization are key factors in the rapid growth of the healthcare sector. Analysis platforms are currently distributed by health facilities around the world, assisting in patient management, maintenance, due to the best care that can be provided. The distribution of health care analysis platforms not only increases staff productivity, but overall patient management has improved and the burden on caregivers has been reduced. It can not only Excellerate the quality of patient care but also provide information on the overall management of business facilities, better patient access, disease control etc. Hence, the rise in technology advancements is the crucial driver for the growth of the market.

Increasing Government initiatives to Stimulate Market Growth

Government efforts and major financial fluctuations in the healthcare industry also encourage the renaming and are responsible for the increased acceptance of these analysis platforms by health facilities. Analytical forums are used not only by hospitals but also by other institutions for the management and interpretation of clinical data from the various studies conducted; to study historical data and analyse it to identify trends, to develop methods, tools and technologies for best results.

These areas of analysis are also used by policy makers to learn statistics and models to make better decisions and policies regarding health care facilities and to provide care to patients. The U.S. government has been taking steps to address this case as the HealthData.gov website contains information from a few state-owned databases on Topics such as public health practices, clinical data, medical information, and engineering information that are accessible through application applications. Therefore, the implementation of these programs is considered a good indicator of market growth as a whole.

Key Insights & Findings from the Report:

  • According to our primary respondents’ research, the Healthcare Analytics market is predicted to grow at a CAGR of roughly 20.9% during the forecast period.

  • The Healthcare Analytics market was estimated to be worth roughly USD 28.5 Billion in 2021 and is expected to reach USD 89 Billion by 2028; based on primary research.

  • On the basis of region, North America is projected to dominate the worldwide Healthcare Analytics market.

Purchase This Premium Report (Price 4500 USD for a single-user license) at @ https://www.vantagemarketresearch.com/buy-now/healthcare-analytics-market-1664/0

Benefits of Purchasing Healthcare Analytics Market Reports:    

  • Customer Satisfaction: Our team of experts assists you with all your research needs and optimizes your reports.

  • Analyst Support: Before or after purchasing the report, ask a professional analyst to address your questions.

  • Assured Quality: Focuses on accuracy and quality of reports.

  • Incomparable Skills: Analysts provide in-depth insights into reports.

Segmentation of the Global Healthcare Analytics Market:

  • Type

    • Descriptive Analytics

    • Predictive Analytics

    • Prescriptive Analytics

    • Cognitive Analytics

  • Application

  • Component

    • Services

    • Hardware

    • Software

  • Deployment Model

  • End User

  • Region

    • North America

    • Europe

    • Asia Pacific

    • Latin America

    • Middle East & Africa

Read Full Research Report @ https://www.vantagemarketresearch.com/industry-report/healthcare-analytics-market-1664

COVID-19 Impact Analysis:

The COVID-19 outbreak has affected various industries worldwide. Governments across the world implemented strict lockdown measures and social distancing norms in order to restrict the swift spread of the pandemic. Manufacturing facilities around the world were shut down during the initial stages of the pandemic. Moreover, the economic crisis after the pandemic might lead to a significant delay in the commercial roll-out of the IT healthcare industry. Small and medium-scale companies are the backbone of technology providers and are witnessing a steep drop in revenue since the emergence of the pandemic in 2020. Hence, market players faced numerous challenges as disruptions in the supply chain were observed. However, things will Excellerate in the second half of 2022 as more supplies will come online. The impact of COVID-19 on the market demand is considered while estimating the current and forecast market size and growth trends of the market for all the regions and countries based on the following data points:

  1. Impact Assessment of COVID-19 Pandemic

    1. North America

    2. Europe

    3. Asia Pacific

    4. Latin America

    5. Middle East & Africa

  2. Quarterly Market Revenue Forecast by Asia Pacific 2020 & 2021

  3. Key Strategies Undertaken by Companies to Tackle COVID-19

  4. Long Term Dynamics

  5. Short Term Dynamics

The report on Healthcare Analytics Market highlights:

  • Assessment of the market

  • Premium Insights

  • Competitive Landscape

  • COVID Impact Analysis

  • Historic Data, Estimates and Forecast

  • Company Profiles

  • Global and Regional Dynamics

Regional Analysis:

North America Dominated the Global Healthcare Analytics Market

North America dominated the Global Healthcare Analytics Market in 2021 and is likely to continue the same trend during the forecast period. This is attributable to the increase in implementation of organizational health regulations that promote the adoption of HCIT solutions in the region. Furthermore, the increasing focus on PHM, greater VC investment along with growing pressure to reduce health care costs is also likely to support the regional growth of the market. Additionally, the high availability of products and services and presence of leading players is also expected to fuel the growth of the market in the region.

Browse market data Tables and Figures spread through 150 Pages and in-depth TOC on "Healthcare Analytics Market Size, Share & Trends Analysis Report by Type (Descriptive Analytics, Predictive Analytics, Prescriptive Analytics, Cognitive Analytics), by Application (Clinical Analytics, Financial Analytics, Operation and Administrative Analytics, Population Health), by Component (Services, Hardware, Software), by Deployment Model (On-Premise, On-Demand), by End User (Payers, Providers, ACOs, HIEs, Mcos and TPAs), by Region (North America, Europe, Asia Pacific, Latin America) - Global Industry Assessment (2016 - 2021) & Forecast (2022 - 2028)".

List of Prominent Players in Healthcare Analytics Market:

Recent Developments:

July 2021: Enlitic (US) got in partnership with NMC Healthcare (UAE). This is a multi-faceted partnership with private healthcare companies to implement Enlitic solutions in GCC countries.

June 2021: Flatiron (US) collaborated with Foundation Medicine, Inc. to integrate its solutions with OncoEMR to provide customers with integrated genetic profiles.

April 2020: Cerner announced the acquisition Kantar Health. With this discovery, Cerner plans to compile data to Excellerate the safety and effectiveness of clinical research in health sciences, medicine, and health care. This acquisition is expected to add to your service delivery.

January 2020: Optum and Change Healthcare, a healthcare technology provider, announced their partnership. Under this partnership, Change Healthcare will join Optum Insight in delivering software and data analysis, technology-based services, research, and revenue management cycle offerings to strengthen Optum’s healthcare analysis portfolio.

Key questions answered in the report:

  • Which regional market will show the highest and rapid growth?

  • Which are the top five players of the Healthcare Analytics Market?

  • How will the Healthcare Analytics Market change in the upcoming six years?

  • Which application and product will take a lion’s share of the Healthcare Analytics Market?

  • What is the Healthcare Analytics market drivers and restrictions?

  • What will be the CAGR and size of the Healthcare Analytics Market throughout the forecast period?

This market titled “Healthcare Analytics Market” will cover exclusive information in terms of Regional Analysis, Forecast, and Quantitative Data – Units, Key Market Trends, and various others as mentioned below:

Parameter

Details

Market Size Provided for Years

2016-2028

Base Year

2021

Historic Years

2016-2020

Forecast Years

2022-2028

Segments Covered

• Type

   • Descriptive Analytics

   • Predictive Analytics

   • Prescriptive Analytics

   • Cognitive Analytics

• Application

   • Clinical Analytics

   • Financial Analytics

   • Operation and Administrative Analytics

   • Population Health

• Component

   • Services

   • Hardware

   • Software

• Deployment Model

   • On-Premise

   • On-Demand

• End User

   • Payers

   • Providers

   • ACOs, HIEs, Mcos and TPAs

• Region

   • North America

   • Europe

   • Asia Pacific

   • Latin America

   • Middle East & Africa

Region & Counties Covered

• North America

    • U.S.

    • Canada

    • Mexico

• Europe

    • U.K

    • France

    • Germany

    • Italy

    • Spain

    • Rest Of Europe

• Asia Pacific

    • China

    • Japan

    • India

    • South Korea

    • South East Asia

    • Rest Of Asia Pacific

• Latin America

    • Brazil

    • Argentina

    • Rest Of Latin America

• Middle East & Africa

    • GCC Countries

    • South Africa

    • Rest Of Middle East & Africa

Companies Covered

• IBM (US)

• Optum (US)

• Cerner (US)

• SAS Institute (US)

• Allscripts (US)

• McKesson (US)

• MedeAnalytics (US)

• Inovalon (US)

• Oracle (US)

• Health Catalyst (US)

• SCIO Health Analytics (US)

• Cotiviti (formerly Verscend Technologies) (US)

• CitiusTech (US)

• Wipro (India)

• VitreosHealth (US)

• Linguamatics (US)

• Flatiron (US)

• Roam Analytics (US)

• Komodo Health (US)

• CVS Health (US)

Report Coverage

Market growth drivers, restraints, opportunities, Porter’s five forces analysis,
PEST analysis, value chain analysis, regulatory landscape, technology landscape,
patent analysis, market attractiveness analysis by segments and North America,
company market share analysis, and COVID-19 impact analysis

Customization of the Report:

The report can be customized as per client needs or requirements. For any queries, you can contact us on sales@vantagemarketresearch.com or +1 (202) 380-9727. Our sales executives will be happy to understand your needs and provide you with the most suitable reports.

Download Free demo Report Now @ https://www.vantagemarketresearch.com/healthcare-analytics-market-1664/request-sample

Browse More Related Report:

  • Cross-Border B2C E-Commerce Market to Reach Valuation of USD 3,042.2 Million by 2028 - The growth of online stores and e-commerce purchasing is Driving the Market Growth.

  • Cannabis Testing Market to Reach USD 2,669.45 Million by 2028.

  • B2B Payments Market to Reach 1,618.15 USD Billion by 2028.

  • Electric Truck Market to Reach Valuation of USD 1686.6 Million by 2028 - The Government's Focus on Zero-Emission Cars and Rules will Encourage the Use of Electric Trucks in the E-Commerce and Automotive Industries.

  • Ethanol Market to Reach Valuation of USD 117.5 Billion by 2028 – Changing Lifestyle and Disposable Income among the Global Population Drives the Market.

  • Green Hydrogen – The Future Fuel Set to Witness 50 - Fold Growth Increasing Investments & Government Policies to Boost Global Green Hydrogen Market.

  • Green Chemicals Market to Reach Valuation of 16684.27 USD Million by 2028; Increasing Adoption of Packaging Which is Bio-based is Driving the Market.

About Vantage Market Research:

We, at Vantage Market Research, provide quantified B2B high quality research on more than 20,000 emerging markets, in turn, helping our clients map out constellation of opportunities for their businesses. We, as a competitive intelligence market research and consulting firm provide end to end solutions to our client enterprises to meet their crucial business objectives. Our clientele base spans across 70% of Global Fortune 500 companies. The company provides high quality data and market research services. The company serves various enterprises and clients in a wide variety of industries. The company offers detailed reports on multiple industries including Chemical Materials and Energy, Food and Beverages, Healthcare Technology, etc. The company’s experienced team of Analysts, Researchers, and Consultants use proprietary data sources and numerous statistical tools and techniques to gather and analyse information.

Follow Us on LinkedIn: https://www.linkedin.com/company/vantage-market-research/

Follow Us on Twitter: https://twitter.com/vantagemarketr

Contact us

Eric Kunz

6218 Georgia Avenue NW Ste 1 - 564

Washington DC 20011-5125

United States Tel: +1 202 380 9727

Email: sales@vantagemarketresearch.com

Website: https://www.vantagemarketresearch.com/

Latest Vantage Market Research Press Releases @https://www.vantagemarketresearch.com/insight/press-releases

Latest Vantage Market Research Blog @ https://www.vantagemarketresearch.com/insight/blogs

Blog:

Mon, 20 Jun 2022 23:10:00 -0500 en-CA text/html https://ca.finance.yahoo.com/news/insights-89-bn-healthcare-analytics-110600316.html
A00-250 exam dump and training guide direct download
Training Exams List